TG Therapeutics (TGTX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

TGTX Stock Forecast

TG Therapeutics stock forecast is as follows: an average price target of $27.60 (represents a -6.57% downside from TGTX’s last price of $29.54) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

TGTX Price Target

The average price target for TG Therapeutics (TGTX) is $27.60 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $55.00 to $16.00. This represents a potential -6.57% downside from TGTX's last price of $29.54.

TGTX Analyst Ratings

Buy

According to 7 Wall Street analysts, TG Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TGTX stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

TG Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 05, 2024	Edward White	H.C. Wainwright	$55.00	$25.86	112.68%	86.19%
Aug 06, 2024	Corinne Jenkins	Goldman Sachs	$20.00	$20.58	-2.82%	-32.30%
May 03, 2024	Edward White	H.C. Wainwright	$49.00	$16.42	198.42%	65.88%
Feb 07, 2023	-	Cantor Fitzgerald	$24.00	$18.48	29.87%	-18.75%
Dec 30, 2022	-	Evercore ISI	$16.00	$11.83	35.25%	-45.84%
Dec 29, 2022	Edward White	H.C. Wainwright	$24.00	$8.46	183.69%	-18.75%
Apr 19, 2022	-	Goldman Sachs	$5.00	$7.26	-31.13%	-83.07%
Apr 18, 2022	Mayank Mamtani	Telsey Advisory	$23.00	$6.92	232.37%	-22.14%

Row per page

Go to

The latest TG Therapeutics stock forecast, released on Nov 05, 2024 by Edward White from H.C. Wainwright, set a price target of $55.00, which represents a 112.68% increase from the stock price at the time of the forecast ($25.86), and a 86.19% increase from TGTX last price ($29.54).

TG Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	1	1	3
Avg Price Target	$55.00	$55.00	$41.33
Last Closing Price	$29.54	$29.54	$29.54
Upside/Downside	86.19%	86.19%	39.91%

In the current month, the average price target of TG Therapeutics stock is $55.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 86.19% increase as opposed to TG Therapeutics's last price of $29.54. This month's average price target is down 0.00% compared to last quarter, and up 33.08% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 29, 2024	H.C. Wainwright	Buy	Buy	Hold
Oct 29, 2024	Cowen & Co.	-	Buy	Initialise
Oct 24, 2024	B. Riley	Buy	Buy	Hold
Sep 18, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 06, 2024	Goldman Sachs	Neutral	Neutral	Hold
May 03, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 02, 2023	Goldman Sachs	Sell	Neutral	Upgrade
Dec 30, 2022	Jefferies	Buy	Buy	Hold
Dec 30, 2022	Goldman Sachs	Sell	Sell	Hold
Dec 30, 2022	Evercore ISI	Outperform	Outperform	Hold

Row per page

Go to

TG Therapeutics's last stock rating was published by H.C. Wainwright on Oct 29, 2024. The company gave TGTX a "Buy" rating, the same as its previous rate.

TG Therapeutics Financial Forecast

TG Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
Revenue	-	-	-	-	-	-	-	-	$43.97M	$165.81M	$16.07M	$7.80M	$80.00K	$94.00K	$594.00K	$2.02M	$2.32M	$2.03M	$1.54M	$793.00K	$38.00K	$38.00K	$38.00K	$38.00K	$38.00K	$38.00K	$38.00K	$38.00K
Avg Forecast	$172.50M	$142.53M	$127.30M	$110.84M	$98.80M	$81.70M	$65.92M	$54.60M	$40.06M	$23.91M	$17.39M	$3.38M	$1.60M	$1.46M	$175.43K	$2.08M	$2.24M	$2.97M	$3.60M	$820.29K	$19.00K	$19.00K	$22.80K	$22.80K	$22.80K	$34.50K	$19.00K	$25.33K
High Forecast	$181.52M	$149.98M	$133.96M	$114.99M	$103.46M	$81.94M	$65.92M	$54.60M	$40.18M	$23.91M	$18.30M	$3.56M	$1.69M	$1.46M	$175.43K	$2.08M	$2.24M	$2.97M	$3.60M	$820.29K	$19.00K	$19.00K	$22.80K	$22.80K	$22.80K	$34.50K	$19.00K	$25.33K
Low Forecast	$164.54M	$135.95M	$121.42M	$106.69M	$95.05M	$81.47M	$65.92M	$54.60M	$39.88M	$23.91M	$16.59M	$3.22M	$1.53M	$1.46M	$175.43K	$2.08M	$2.24M	$2.97M	$3.60M	$820.29K	$19.00K	$19.00K	$22.80K	$22.80K	$22.80K	$34.50K	$19.00K	$25.33K
# Analysts	1	1	1	3	6	3	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4	4	4	3	3	3	3
Surprise %	-	-	-	-	-	-	-	-	1.10%	6.93%	0.92%	2.31%	0.05%	0.06%	3.39%	0.97%	1.04%	0.68%	0.43%	0.97%	2.00%	2.00%	1.67%	1.67%	1.67%	1.10%	2.00%	1.50%

TG Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $54.60M, with a low forecast of $54.60M, and a high forecast of $54.60M. TGTX's average Quarter revenue forecast represents a 24.18% increase compared to the company's last Quarter revenue of $43.97M (Dec 23).

TG Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	3	6	3	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4	4	4	3	3	3	3
EBITDA	-	-	-	-	-	-	-	-	$-12.48M	$114.78M	$-43.98M	$-36.39M	$-50.13M	$-34.04M	$-37.49M	$-66.22M	$-92.18M	$-84.52M	$-76.81M	$-88.67M	$-86.87M	$-85.51M	$-50.62M	$-49.88M	$-37.65M	$-60.37M	$-35.11M	$-35.13M
Avg Forecast	$-134.15M	$-110.84M	$-99.00M	$-86.19M	$-76.83M	$-63.54M	$-51.27M	$-42.46M	$-31.16M	$-18.60M	$-13.53M	$-2.63M	$-1.25M	$-1.14M	$-137.18K	$-49.39M	$-1.75M	$-2.32M	$-2.82M	$-57.73M	$-14.86K	$-66.09M	$-17.83K	$-17.83K	$-17.83K	$-26.98K	$-14.86K	$-19.81K
High Forecast	$-127.95M	$-105.72M	$-94.43M	$-82.97M	$-73.91M	$-63.36M	$-51.27M	$-42.46M	$-31.02M	$-18.60M	$-12.90M	$-2.51M	$-1.19M	$-1.14M	$-137.18K	$-39.51M	$-1.75M	$-2.32M	$-2.82M	$-46.18M	$-14.86K	$-52.87M	$-17.83K	$-17.83K	$-17.83K	$-26.98K	$-14.86K	$-19.81K
Low Forecast	$-141.16M	$-116.64M	$-104.17M	$-89.42M	$-80.46M	$-63.72M	$-51.27M	$-42.46M	$-31.25M	$-18.60M	$-14.23M	$-2.77M	$-1.31M	$-1.14M	$-137.18K	$-59.26M	$-1.75M	$-2.32M	$-2.82M	$-69.27M	$-14.86K	$-79.30M	$-17.83K	$-17.83K	$-17.83K	$-26.98K	$-14.86K	$-19.81K
Surprise %	-	-	-	-	-	-	-	-	0.40%	-6.17%	3.25%	13.85%	40.19%	29.90%	273.31%	1.34%	52.63%	36.42%	27.25%	1.54%	5847.34%	1.29%	2839.31%	2797.97%	2111.45%	2237.64%	2363.40%	1773.59%

5 analysts predict TGTX's average Quarter EBITDA for Dec 23 to be $-31.16M, with a high of $-31.02M and a low of $-31.25M. This is -127.14% lower than TG Therapeutics's previous annual EBITDA (Sep 23) of $114.78M.

TG Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	3	6	3	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4	4	4	3	3	3	3
Net Income	-	-	-	-	-	-	-	-	$-14.42M	$113.93M	$-47.61M	$-38.63M	$-53.92M	$-36.67M	$-42.08M	$-71.15M	$-93.73M	$-86.15M	$-79.50M	$-92.05M	$-89.65M	$-88.60M	$-54.92M	$-51.99M	$-41.18M	$-63.00M	$-36.88M	$-35.62M
Avg Forecast	$55.04M	$40.82M	$32.46M	$21.21M	$14.46M	$4.82M	$-7.33M	$-9.64M	$-16.11M	$9.19M	$-40.42M	$-58.26M	$-43.57M	$-56.60M	$-76.52M	$-51.45M	$-101.23M	$-90.87M	$-82.90M	$-59.00M	$-95.43M	$-67.36M	$-53.89M	$-57.07M	$-73.02M	$-53.81M	$-64.83M	$-69.35M
High Forecast	$58.79M	$43.60M	$34.67M	$23.34M	$19.89M	$5.15M	$-6.89M	$-9.06M	$-13.43M	$9.81M	$-37.99M	$-54.76M	$-40.96M	$-56.60M	$-76.52M	$-41.16M	$-101.23M	$-90.87M	$-82.90M	$-47.20M	$-95.43M	$-53.89M	$-53.89M	$-57.07M	$-73.02M	$-53.81M	$-64.83M	$-69.35M
Low Forecast	$51.74M	$38.37M	$30.51M	$19.09M	$10.85M	$4.53M	$-7.83M	$-10.30M	$-17.46M	$8.63M	$-43.17M	$-62.22M	$-46.53M	$-56.60M	$-76.52M	$-61.74M	$-101.23M	$-90.87M	$-82.90M	$-70.80M	$-95.43M	$-80.83M	$-53.89M	$-57.07M	$-73.02M	$-53.81M	$-64.83M	$-69.35M
Surprise %	-	-	-	-	-	-	-	-	0.89%	12.40%	1.18%	0.66%	1.24%	0.65%	0.55%	1.38%	0.93%	0.95%	0.96%	1.56%	0.94%	1.32%	1.02%	0.91%	0.56%	1.17%	0.57%	0.51%

TG Therapeutics's average Quarter net income forecast for Dec 23 is $-16.11M, with a range of $-17.46M to $-13.43M. TGTX's average Quarter net income forecast represents a -114.14% decrease compared to the company's last Quarter net income of $113.93M (Sep 23).

TG Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	3	6	3	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4	4	4	3	3	3	3
SG&A	-	-	-	-	-	-	-	-	$31.15M	$26.50M	$36.38M	$29.65M	$28.26M	$17.50M	$14.97M	$22.50M	$56.46M	$34.90M	$34.02M	$26.76M	$43.86M	$35.30M	$14.43M	$14.26M	$7.06M	$2.91M	$2.72M	$2.34M
Avg Forecast	$34.21B	$28.27B	$25.25B	$21.98B	$19.59B	$16.20B	$13.07B	$10.83B	$7.95B	$4.74B	$3.45B	$670.15M	$318.16M	$288.71M	$34.79M	$412.66M	$444.22M	$588.55M	$714.97M	$162.69M	$3.77M	$3.77M	$4.52M	$4.52M	$4.52M	$6.84M	$3.77M	$5.02M
High Forecast	$36.00B	$29.75B	$26.57B	$22.81B	$20.52B	$16.25B	$13.07B	$10.83B	$7.97B	$4.74B	$3.63B	$705.20M	$334.80M	$288.71M	$34.79M	$412.66M	$444.22M	$588.55M	$714.97M	$162.69M	$3.77M	$3.77M	$4.52M	$4.52M	$4.52M	$6.84M	$3.77M	$5.02M
Low Forecast	$32.63B	$26.96B	$24.08B	$21.16B	$18.85B	$16.16B	$13.07B	$10.83B	$7.91B	$4.74B	$3.29B	$639.21M	$303.47M	$288.71M	$34.79M	$412.66M	$444.22M	$588.55M	$714.97M	$162.69M	$3.77M	$3.77M	$4.52M	$4.52M	$4.52M	$6.84M	$3.77M	$5.02M
Surprise %	-	-	-	-	-	-	-	-	0.00%	0.01%	0.01%	0.04%	0.09%	0.06%	0.43%	0.05%	0.13%	0.06%	0.05%	0.16%	11.64%	9.37%	3.19%	3.15%	1.56%	0.43%	0.72%	0.47%

TG Therapeutics's average Quarter SG&A projection for Mar 24 is $10.83B, based on 4 Wall Street analysts, with a range of $10.83B to $10.83B. The forecast indicates a 34662.42% rise compared to TGTX last annual SG&A of $31.15M (Dec 23).

TG Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	3	6	3	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4	4	4	3	3	3	3
EPS	-	-	-	-	-	-	-	-	$-0.10	$0.80	$-0.34	$-0.28	$-0.39	$-0.27	$-0.31	$-0.53	$-0.71	$-0.65	$-0.60	$-0.70	$-0.72	$-0.74	$-0.49	$-0.49	$-0.43	$-0.70	$-0.42	$-0.44
Avg Forecast	$0.34	$0.25	$0.20	$0.13	$0.09	$0.03	$-0.05	$-0.06	$-0.10	$0.06	$-0.25	$-0.36	$-0.27	$-0.35	$-0.48	$-0.61	$-0.64	$-0.57	$-0.52	$-0.56	$-0.60	$-0.41	$-0.34	$-0.36	$-0.46	$-0.34	$-0.41	$-0.43
High Forecast	$0.37	$0.27	$0.22	$0.15	$0.12	$0.03	$-0.04	$-0.06	$-0.08	$0.06	$-0.24	$-0.34	$-0.25	$-0.35	$-0.48	$-0.61	$-0.64	$-0.57	$-0.52	$-0.56	$-0.60	$-0.41	$-0.34	$-0.36	$-0.46	$-0.34	$-0.41	$-0.43
Low Forecast	$0.32	$0.24	$0.19	$0.12	$0.07	$0.03	$-0.05	$-0.06	$-0.11	$0.05	$-0.27	$-0.39	$-0.29	$-0.35	$-0.48	$-0.61	$-0.64	$-0.57	$-0.52	$-0.56	$-0.60	$-0.41	$-0.34	$-0.36	$-0.46	$-0.34	$-0.41	$-0.43
Surprise %	-	-	-	-	-	-	-	-	1.00%	14.00%	1.35%	0.77%	1.44%	0.76%	0.65%	0.87%	1.12%	1.14%	1.15%	1.26%	1.20%	1.79%	1.45%	1.37%	0.94%	2.07%	1.03%	1.01%

According to 5 Wall Street analysts, TG Therapeutics's projected average Quarter EPS for Dec 23 is $-0.10, with a low estimate of $-0.11 and a high estimate of $-0.08. This represents a -112.53% decrease compared to TGTX previous annual EPS of $0.80 (Sep 23).

TG Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.68	$70.00	10194.12%	Buy
BTAI	BioXcel Therapeutics	$0.57	$12.00	2005.26%	Buy
XFOR	X4 Pharmaceuticals	$0.40	$3.67	817.50%	Buy
PDSB	PDS Bio	$2.01	$9.00	347.76%	Buy
TERN	Terns Pharmaceuticals	$6.17	$14.25	130.96%	Buy
VKTX	Viking Therapeutics	$49.58	$102.40	106.53%	Buy
AKRO	Akero Therapeutics	$28.09	$46.00	63.76%	Buy
MDGL	Madrigal Pharmaceuticals	$288.58	$315.75	9.42%	Buy
TGTX	TG Therapeutics	$29.54	$27.60	-6.57%	Buy
EXEL	Exelixis	$34.45	$30.50	-11.47%	Buy

TGTX Forecast FAQ

Is TG Therapeutics a good buy?

Yes, according to 7 Wall Street analysts, TG Therapeutics (TGTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 85.71% of TGTX's total ratings.

What is TGTX's price target?

TG Therapeutics (TGTX) average price target is $27.6 with a range of $16 to $55, implying a -6.57% from its last price of $29.54. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will TG Therapeutics stock go up soon?

According to Wall Street analysts' prediction for TGTX stock, the company can go down by -6.57% (from the last price of $29.54 to the average price target of $27.6), up by 86.19% based on the highest stock price target, and down by -45.84% based on the lowest stock price target.

Can TG Therapeutics stock reach $40?

TGTX's highest twelve months analyst stock price target of $55 supports the claim that TG Therapeutics can reach $40 in the near future.

What is TG Therapeutics's current price target trend?

1 Wall Street analyst forecast a $55 price target for TG Therapeutics (TGTX) this month, up 86.19% from its last price of $29.54. Compared to the last 3 and 12 months, the average price target increased by 86.19% and increased by 39.91%, respectively.

What are TG Therapeutics's analysts' financial forecasts?

TG Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $301.03M (high $305.93M, low $297.04M), average EBITDA is $-234M (high $-231M, low $-238M), average net income is $2.31M (high $9.08M, low $-2.748M), average SG&A $59.7B (high $60.67B, low $58.91B), and average EPS is $0.0144 (high $0.0565, low $-0.0171). TGTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $553.17M (high $580.45M, low $528.59M), average EBITDA is $-430M (high $-411M, low $-451M), average net income is $149.54M (high $160.39M, low $139.72M), average SG&A $109.71B (high $115.12B, low $104.83B), and average EPS is $0.93 (high $0.998, low $0.869).

Did the TGTX's actual financial results beat the analysts' financial forecasts?

Based on TG Therapeutics's last annual report (Dec 2023), the company's revenue was $233.66M, beating the average analysts forecast of $84.75M by 175.71%. Apple's EBITDA was $20.63M, missing the average prediction of $-65.906M by -131.31%. The company's net income was $12.67M, missing the average estimation of $-106M by -112.00%. Apple's SG&A was $122.71M, missing the average forecast of $16.81B by -99.27%. Lastly, the company's EPS was $0.0853, missing the average prediction of $-0.657 by -112.98%. In terms of the last quarterly report (Dec 2023), TG Therapeutics's revenue was $43.97M, beating the average analysts' forecast of $40.06M by 9.75%. The company's EBITDA was $-12.485M, missing the average prediction of $-31.156M by -59.93%. TG Therapeutics's net income was $-14.416M, missing the average estimation of $-16.115M by -10.54%. The company's SG&A was $31.15M, missing the average forecast of $7.95B by -99.61%. Lastly, the company's EPS was $-0.1, missing the average prediction of $-0.1 by -0.27%